BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Inhibiting MAO-B or GABRA5 could treat subcortical stroke by restoring regional glucose metabolism and alleviating diaschisis, neurological dormancy at sites distant from a focal brain injury. In a rat model...
BioCentury | Jun 20, 2020
Product Development

Regeneron’s commercial future

As its long-standing tie-up with Sanofi winds down, the main loss Regeneron faces is access to the pharma’s commercial footprint, as the biotech has yet to build one for itself. An analysis of Regeneron’s wholly...
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively...
BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

ChemoCentryx therapy fails Phase II study in rare renal disorder ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

A day after Arch and Flagship unveiled dueling billion dollar funds, venBio is staying the course with a more modest $394 million fund. What is new for the nine-year-old firm is a dramatic shift away...
BioCentury | Mar 21, 2020
Finance

Design debuts with $45M series A, portfolio against repeat expansions

Design Therapeutics emerged from stealth Friday with a $45 million series A and a portfolio of bifunctional small molecules to treat degenerative disorders caused by nucleotide repeat expansions, starting with Friedreich's ataxia. SR One led...
BioCentury | Mar 20, 2020
Product Development

Industry to boost supply of chloroquine, hydroxychloroquine despite limited data in COVID-19

Novartis and Teva join a growing list of pharmas with plans to ramp up supply of antimalarial drug hydroxychloroquine in the U.S. for COVID-19 despite sparse clinical data supporting the drug's efficacy in the indication....
BioCentury | Mar 19, 2020
Product Development

DARPA’s gambles might have created the best hopes for stopping COVID-19

A U.S. defense agency that specializes in turning science fantasies into realities jump-started technologies and nurtured companies that are now at the forefront of the response to the COVID-19 pandemic. The Defense Research Advanced Projects...
Items per page:
1 - 10 of 2188